The Danish Medicines Agency has published the latest findings from the country’s ongoing medical cannabis pilot programme.
Denmark launched its medicinal cannabis pilot programme in 2018, allowing doctors to prescribe cannabis-based products for patients with certain qualifying conditions.
Now officials have published the latest findings from the programme, which is expected to run until 2025.
The report outlines key information regarding suspected adverse reactions, consumption trends and overall safety of prescribed cannabis products during the period of 2021-2022.
Overview of side effects
During the specified period, the agency received 19 reports of suspected adverse reactions related to cannabis products covered by the pilot programme. This is a significant reduction from the 20 reports received in 2020.